文献速递肝病

合并症对无干扰素治疗诱导丙型肝炎病毒清除后患者结局的影响

Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.
PubMed 文献 · J Hepatol · 2017-12-28

前瞻性非干预研究纳入14家西班牙大学医院接受直接抗病毒药物治疗的HCV感染患者,随访至死亡或满2年。1年内死亡率3.4%(65/1891),研究期间死亡率5.4%(102/1891)。HepCom评分(整合Charlson合并症指数、年龄及肝功能指标)对1年和2年死亡率的区分度C统计量为0.90,优于MELD(0.81)、Child-Pugh(0.72)和CirCom(0.68)。

要点

  • HCV感染者启动直接抗病毒药物后1年内死亡率为3.4%(65/1891),研究期间死亡率为5.4%(102/1891)。
  • 校正肝硬化、血小板计数、丙氨酸氨基转移酶和性别后,Charlson指数(HR 1.55)、胆红素(HR 1.39)、年龄(HR 1.06)、INR(HR 3.49)与1年死亡率独立相关,白蛋白(HR 0.18)与降低的1年死亡率独立相关。
  • HepCom评分低危组(≤5.7分)死亡率为2%-3%,高危组(≥25分)死亡率为56%-59%,在估算队列和验证队列中均一致。

核心结论

  • HepCom评分由Charlson合并症指数、年龄及肝功能指标(INR、白蛋白、胆红素)组成,可识别启动直接抗病毒药物治疗后1年和2年死亡及临床事件高风险的患者组。

研究设计与样本

  • 前瞻性非干预研究,纳入14家西班牙大学医院,从直接抗病毒治疗开始随访至死亡或满2年,患者为接受直接抗病毒药物治疗的HCV感染者,不限肝纤维化分期,用于构建估算队列和验证队列。

主要发现

  • 1年内死亡3.4%(65/1891),研究期间死亡5.4%(102/1891)。
  • 校正肝硬化、血小板计数、丙氨酸氨基转移酶和性别后,Charlson指数(HR 1.55;95%CI 1.29-1.86;p=0.0001)、胆红素(HR 1.39;95%CI 1.11-1.75;p=0.004)、年龄(HR 1.06;95%CI 1.02-1.11;p=0.005)、INR(HR 3.49;95%CI 1.36-8.97;p=0.010)与1年死亡率独立相关,白蛋白(HR 0.18;95%CI 0.09-0.37;p=0.0001)与降低的1年死亡率独立相关。
  • HepCom评分校准和区分度良好(C统计量0.90),对1年和2年死亡率优于MELD(0.81)、Child-Pugh(0.72)和CirCom(0.68)。
  • HepCom评分低危组(≤5.7分)死亡率为2%-3%,高危组(≥25分)死亡率为56%-59%,在估算队列和验证队列中均一致;两组临床事件分布相似。

关键数值与推荐

  • HepCom评分低危组(≤5.7分)死亡率为2%-3%,高危组(≥25分)死亡率为56%-59%。
  • HepCom评分对1年和2年死亡率的C统计量为0.90,MELD为0.81,Child-Pugh为0.72,CirCom为0.68。

临床怎么用

  • 作者指出,合并症严重患者的预后可能不会从HCV病毒清除中获益。
  • 作者指出,需要一个算法来决定谁将从治疗中获益,以更好地管理慢性HCV感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with advanced liver fibrosis remain at risk of cirrhosis-related outcomes and those with severe comorbidities may not benefit from hepatitis C (HCV) eradication. We aimed to collect data on all-cause mortality and relevant clinical events within the first two years of direct-acting antiviral therapy, whilst determining the prognostic capability of a comorbidity-based model. METHODS: This was a prospective non-interventional study, from the beginning of direct-acting antiviral therapy to the event of interest (mortality) or up to two years of follow-up, including 14 Spanish University Hospitals. Patients with HCV infection, irrespective of liver fibrosis stage, who received direct-acting antiviral therapy were used to build an estimation and a validation cohort. Comorbidity was assessed according to Charlson comorbidity and CirCom indexes. RESULTS: A total of 3.4% (65/1,891) of individuals died within the first year, while 5.4% (102/1,891) died during the study. After adjusting for cirrhosis, platelet count, alanine aminotransferase and sex, the following factors were independently associated with one-year mortality: Charlson index (hazard ratio [HR] 1.55; 95% CI 1.29-1.86; p = 0.0001), bilirubin (HR 1.39; 95% CI 1.11-1.75; p = 0.004), age (HR 1.06 95% CI 1.02-1.11; p = 0.005), international normalized ratio (HR 3.49; 95% CI 1.36-8.97; p = 0.010), and albumin (HR 0.18; 95% CI 0.09-0.37; p = 0.0001). HepCom score showed a good calibration and discrimination (C-statistics 0.90), and was superior to the other prognostic scores (model for end-stage liver disease 0.81, Child-Pugh 0.72, CirCom 0.68) regarding one- and two-year mortality. HepCom score identified low- (≤5.7 points: 2%-3%) and high-risk (≥25 points: 56%-59%) mortality groups, both in the estimation and validation cohorts. The distribution of clinical events was similar between groups. CONCLUSIONS: The HepCom score, a combination of Charlson comorbidity index, age, and liver function (international normalized ratio, albumin, and bilirubin) enables detection of a group at high risk of one- and two-year mortality, and relevant clinical events, after starting direct-acting antiviral therapy. LAY SUMMARY: The prognosis of patients with severe comorbidities may not benefit from HCV viral clearance. An algorithm to decide who will benefit from the treatment is needed to manage the chronic HCV infection better.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ampuero J, Jimeno C, Quiles R, et al. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. J Hepatol. 2017. PMID: 29288753. doi:10.1016/j.jhep.2017.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。